Niraparib for Ovarian Cancer User Reviews (Page 3)
Brand names: Zejula
Niraparib has an average rating of 6.5 out of 10 from a total of 47 reviews for the treatment of Ovarian Cancer. 53% of reviewers reported a positive experience, while 28% reported a negative experience.
Reviews for Niraparib
- Anonymous
- Taken for 1 to 6 months
- November 8, 2017
Zejula (niraparib) "Had every side effect listed.."
- Mememe
- September 12, 2019
Zejula (niraparib) "Jejula has not helped me, and my doctor has said I should not continue taking it. I had just gotten a 90-day supply (180 100-mg pills). Pill containers are still sealed. "
Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.
Learn more about Ovarian Cancer
Care guides
Symptoms and treatments
Medicine.com guides (external)
More about niraparib
- Check interactions
- Compare alternatives
- Reviews (61)
- Side effects
- Dosage information
- During pregnancy
- Drug class: PARP inhibitors
- Breastfeeding
- En español
Zejula (niraparib) "Took for 3 months platlets and hemoglobin have never returned to normal requiring transfusions and I had a stroke. Been off drug now for 2 months had another transfusion two days ago."